These include 99mTc-MIP-1404 and derivatives, and 99mTc-PSMA-I&S, which target PSMA (prostate specific membrane antigen) receptors that are overexpressed in prostate cancer.6,7 In 99mTc-MIP-1404, the tridentate N3 chelator (Chart 1) coordinates to a fac-[99mTc(CO)3]+ moiety.6 In 99mTc-PSMA-I&S (Chart 1), a modified tripeptide, mercaptoacetyl-d-Ser-d-Ser-d-Ser, coordinates to the [99mTcO]3+ motif, via a thiol and three deprotonated amide groups.7 These PSMA-targeted radiopharmaceuticals are prepared from kits. This evidence concerns the gene FOLH1 and prostate cancer.